Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17175
Title: Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).
Austin Authors: Chia, Puey Ling ;John, Thomas 
Affiliation: School of Cancer Medicine, La Trobe University, Victoria, Australia
Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Issue Date: Jun-2016
Publication information: Journal of immunotherapy 2016; 39(5): 202-204
Abstract: Immunomodulatory agents that target PD-1 and its ligand (PD-L1) are being increasingly used in the management of lung cancer. Potential immune-related adverse events include dermatological complications which mostly are of low grade severity. The use of immune checkpoint inhibitors may lead to the exacerbation of autoimmune conditions. We report a case of a documented psoriasis flare with anti-PD-1 treatment for lung cancer.
URI: https://ahro.austin.org.au/austinjspui/handle/1/17175
DOI: 10.1097/CJI.0000000000000121
Journal: Journal of immunotherapy
PubMed URL: 27163740
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27163740
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

20
checked on Jul 15, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.